NR5A1 Antibody

What is NR5A1 and why is it an important research target?

NR5A1 (Nuclear Receptor Subfamily 5 Group A Member 1), also known as Steroidogenic Factor 1 (SF-1), is a key transcriptional activator essential for sexual differentiation and formation of primary steroidogenic tissues. It functions as a nuclear receptor that binds DNA as a monomer and regulates multiple genes involved in the hypothalamic-pituitary-steroidogenic axis.

NR5A1 is critically important in research because:

• It regulates steroidogenic enzyme gene expression

• It plays vital roles in adrenal and gonadal development

• Mutations in NR5A1 are associated with a spectrum of reproductive disorders including male infertility, disorders of sex development (DSD), and primary ovarian insufficiency

• It exhibits tissue-specific expression patterns in steroidogenic tissues, making it an excellent marker for studying development and function of these tissues

The protein consists of a DNA-binding domain (DBD) with two zinc fingers, a flexible hinge region, a ligand-binding domain (LBD), and two activation function domains (AF-1 and AF-2) .

What are the recommended sample types and applications for NR5A1 antibodies?

Based on validation studies, NR5A1 antibodies have been successfully used in multiple applications and sample types:

Note that antigen retrieval with TE buffer pH 9.0 is suggested for IHC applications, although citrate buffer pH 6.0 may also be used as an alternative .

How should researchers interpret subcellular localization patterns of NR5A1?

NR5A1 predominantly localizes to the nucleus, consistent with its function as a transcription factor. When performing immunofluorescence or IHC:

• Expect strong nuclear staining in positive cell types (Sertoli cells, Leydig cells, adrenocortical cells, gonadotropes)

• Cytoplasmic staining should be evaluated carefully as it may represent non-specific binding

• In human testis, specific staining has been localized to cell nuclei in sperm cells

• In cell lines like HepG2, specific staining is consistently localized to cell nuclei

Immunofluorescence studies with wild-type and R350W NR5A1 expression vectors showed identical nuclear localization patterns, indicating that certain mutations may affect transcriptional activity without altering subcellular localization .

What controls should be included when using NR5A1 antibodies?

When designing experiments with NR5A1 antibodies, the following controls are essential:

Positive controls:

• Cell lines with known NR5A1 expression (e.g., HepG2)

• Tissues with confirmed NR5A1 expression:

  • Adrenal cortex

  • Testicular Sertoli and Leydig cells

  • Ovarian theca cells

  • Pituitary gonadotropes

Negative controls:

• Cell lines lacking NR5A1 expression (e.g., K562)

• Tissues that don't express NR5A1

• Secondary antibody-only controls to assess background staining

• Blocking peptide competition assays to confirm specificity

In reporter assays studying NR5A1 function, including known inactivating mutations like p.Gly35Glu as negative controls has proven valuable .

How can researchers validate the specificity of NR5A1 antibodies?

Validation of NR5A1 antibody specificity should include multiple approaches:

• Western blot analysis: Confirm a single band at the expected molecular weight of 52 kDa

• Genetic knockdown/knockout validation:

  • Compare staining in wild-type versus NR5A1 knockout models

  • Use siRNA or shRNA to knockdown NR5A1 and confirm reduction in signal

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide

  • Expected result: reduction or elimination of specific signal

• Tissue specificity:

  • Confirm expression pattern matches known tissue distribution

  • In human studies, NR5A1 antibodies were validated by confirming absence of mutations in over 4000 control alleles, including 370 fertile men and 359 normospermic individuals

• Cross-species validation:

  • Test antibodies on samples from multiple species where sequences are conserved

  • Published studies have confirmed reactivity with human, mouse, and rat samples

What are the recommended antigen retrieval methods for detecting NR5A1 in fixed tissues?

Optimal antigen retrieval methods for NR5A1 detection in formalin-fixed paraffin-embedded (FFPE) tissues:

Primary recommendation:

• TE buffer (Tris-EDTA) at pH 9.0

• Heat-induced epitope retrieval (HIER)

Alternative method:

• Citrate buffer at pH 6.0

• Heat-induced epitope retrieval

In validated IHC protocols, tissues were subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic before incubation with primary antibody. This was followed by detection using anti-mouse IgG HRP polymer antibody and DAB staining with hematoxylin counterstaining .

For transcription factors like NR5A1 that primarily show nuclear localization, proper antigen retrieval is particularly critical to ensure accessibility of nuclear epitopes after fixation.

How can NR5A1 antibodies be used to study male infertility mechanisms?

NR5A1 antibodies are valuable tools for investigating male infertility mechanisms:

Tissue expression studies:

• Immunohistochemical analysis of testicular biopsies to assess NR5A1 expression in patients with unexplained infertility

• Studies have identified NR5A1 mutations in approximately 4% of men with otherwise unexplained severe spermatogenic failure

Functional studies:

• Immunoprecipitation to isolate NR5A1 and associated proteins from testicular samples

• ChIP assays to identify altered binding of mutant NR5A1 to target genes

Mutation analysis workflow:

• Screen for mutations in the NR5A1 gene in infertile men

• Generate expression vectors for identified mutations

• Perform immunofluorescence to assess cellular localization

• Conduct reporter assays to evaluate transcriptional activity

Research has shown that mutations in the hinge region and proximal LBD of NR5A1 lead to impaired transactivation of gonadal promoters. NR5A1 antibodies have been used to demonstrate that these mutations affect regulatory function without altering protein expression or subcellular localization .

What approaches can researchers use to study NR5A1's role in gene regulation?

To investigate NR5A1's regulatory functions:

Chromatin Immunoprecipitation (ChIP):

• Use NR5A1 antibodies to isolate chromatin fragments bound by NR5A1

• Identify target genes regulated by NR5A1

• Compare wild-type binding to that of disease-associated mutants

Reporter Assays:

• Luciferase reporters linked to NR5A1 target promoters (e.g., hTES, CYP17, or AMH)

• Cotransfection with wild-type or mutant NR5A1 expression vectors

• Standardization with Renilla luciferase for accurate quantification

Protein-Protein Interaction Studies:

• Co-immunoprecipitation with NR5A1 antibodies to identify interacting partners

• Immunofluorescence colocalization studies

• Proximity ligation assays to visualize protein interactions in situ

In published research, luciferase assays with hTES and CYP17 promoters demonstrated that mutations like p.R350W significantly impaired transcriptional activities. These assays confirmed the essential role of certain amino acids (like R350) in NR5A1 function in vitro .

How can researchers use NR5A1 antibodies to investigate tissue-specific enhancer function?

NR5A1 antibodies are valuable for studying tissue-specific enhancers controlling NR5A1 expression:

ChIP-seq approaches:

• Use NR5A1 antibodies for chromatin immunoprecipitation followed by sequencing

• Identify genome-wide binding patterns in different tissues

• Compare binding profiles between normal and disease states

Enhancer deletion studies:

• Generate mice lacking specific enhancers (e.g., pituitary enhancer in 6th intron)

• Use immunohistochemistry with NR5A1 antibodies to confirm tissue-specific loss of expression

• Recent studies confirmed that enhancer-deleted mice showed pituitary gland-specific disappearance of NR5A1

Transcriptomic analysis:

• Isolate NR5A1-expressing cells using techniques like FACS with Ad4BP-BAC-EGFP mice

• Perform RNA-seq to identify gonadotrope-specific, NR5A1-dependent gene expression

• Research identified genes like Spp1, Tgfbr3l, Grem1, and Nr0b2 as downstream factors

How should researchers address weak or inconsistent NR5A1 staining?

When encountering weak or inconsistent NR5A1 staining:

For Western blotting:

• Optimize protein extraction methods (nuclear extraction may improve yield)

• Ensure fresh samples and proper handling to prevent protein degradation

• Try different antibody concentrations (recommended range: 1:500-1:1000)

• Consider different blocking reagents to reduce background

• Optimize transfer conditions for higher molecular weight proteins

For IHC/IF:

• Test different antigen retrieval methods (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

• Extend primary antibody incubation (overnight at 4°C vs. shorter incubations)

• Optimize antibody concentration (recommended range: 1:50-1:500 for IHC)

• Consider signal amplification systems for low-expressing samples

• Ensure proper fixation (overfixation can mask epitopes)

For challenging samples, successful protocols have used primary antibody concentrations of 5-8 μg/mL with incubation times of 1-3 hours at room temperature for immunofluorescence, with visualization using fluorophore-conjugated secondary antibodies .

How can researchers distinguish between NR5A1 and its paralog NR5A2?

NR5A1 and NR5A2 share approximately 60% amino acid sequence conservation, requiring careful consideration:

Sequence-specific antibody selection:

• Choose antibodies raised against non-conserved regions

• Verify epitope sequence is unique to NR5A1

• Request information on cross-reactivity testing from manufacturers

Experimental validation:

• Test antibodies on cells/tissues known to express only NR5A1 or NR5A2

• Include appropriate negative controls

• Consider Western blot analysis to confirm correct molecular weight (NR5A1: 52 kDa)

Functional differences to consider:

• Key amino acid differences exist even in conserved domains (e.g., R350 in NR5A1 is replaced by leucine or histidine in NR5A2)

• Reporter assays have demonstrated that these amino acid differences are functionally significant

• The R350 residue in NR5A1 is essential for its function and cannot be substituted with the corresponding amino acid from NR5A2

What data analysis methods are recommended for quantifying NR5A1 expression?

For accurate quantification of NR5A1 expression:

Western blot quantification:

• Use appropriate loading controls (β-actin widely used)

• Apply densitometry software for band intensity analysis

• Normalize NR5A1 signal to loading control

• Run a standard curve with known quantities of recombinant protein

• Present data as mean ± SEM from at least three independent experiments

IHC/IF quantification:

• For nuclear staining, count percentage of positive nuclei

• Use digital image analysis software to quantify staining intensity

• Implement H-score or Allred scoring systems for semi-quantitative analysis

• Consider automated systems for unbiased assessment

• Include multiple fields/sections per sample for statistical robustness

Flow cytometry analysis:

• Use appropriate gating strategies to identify positive populations

• Report median fluorescence intensity (MFI)

• Include fluorescence-minus-one (FMO) controls

• For intracellular staining, use 0.40 μg antibody per 10^6 cells

How are NR5A1 antibodies being used to study novel cofactor interactions?

Recent research has employed NR5A1 antibodies to investigate previously unknown protein-protein interactions:

Potential ligand and cofactor interactions:

• 3D model analysis using SPPIDER server predicted that certain amino acids (like R350) are located on the surface of the ligand-binding domain

• These residues are hypothesized to interact with unidentified endogenous ligands or co-activators

• Mutations at these sites affect transcriptional activity without disrupting protein structure

Known interacting partners:

• The SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter and regulates transcriptional activity

• β-catenin and DAX1 (NR0B1) are confirmed cofactors that interact with the LBD of NR5A1

• 3D modeling predicted that certain residues like R350 are not in direct contact with these known cofactors, suggesting other interaction partners exist

Future research directions:

• Immunoprecipitation with NR5A1 antibodies followed by mass spectrometry to identify novel binding partners

• Proximity labeling methods such as BioID or APEX to map the NR5A1 interactome in different cell types

• Structural studies to elucidate the binding interfaces between NR5A1 and its cofactors

What are the latest methodological advances in studying tissue-specific roles of NR5A1?

Recent technological advances have expanded our understanding of NR5A1's tissue-specific functions:

Genome editing approaches:

• CRISPR/Cas9-mediated deletion of enhancer regions to generate tissue-specific NR5A1 deficiency

• Guide RNAs targeting upstream and downstream regions of enhancers

• Electroporation of RNP complexes into fertilized eggs for efficient genome editing

Cell type-specific isolation:

• Transgenic mouse models like Ad4BP-BAC-EGFP mice enable isolation of NR5A1-expressing gonadotropes

• Fluorescence-activated cell sorting (FACS) to collect specific cell populations

• Single-cell RNA sequencing to identify cell-specific transcriptional profiles

Immunophenotyping:

• Multiplex immunofluorescence to simultaneously detect NR5A1 with cell type-specific markers

• Spatial transcriptomics to correlate protein expression with gene expression patterns

• In situ protein detection combined with laser capture microdissection for cell-specific analyses

These methodological advances have revealed that NR5A1 regulates distinct gene sets in different tissues, providing insight into how the same transcription factor can serve tissue-specific functions during development and in adult organisms.